ET
Edward Tenthoff Piper Sandler Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Alnylam Pharmaceuticals
ALNY
$59.4B
| $453.54 | $449 |
1%
downside
| Overweight | 1 month ago |
|
2
CRISPR Therapeutics
CRSP
$4.8B
| $52.74 | $105 |
99%
upside
| Overweight | 2 months ago |
|
3
Fulcrum Therapeutics
FULC
$372M
| $6.88 | $9 |
31%
upside
| Overweight | 3 months ago |
|
4
Arvinas
ARVN
$559M
| $7.61 | $14 |
84%
upside
| Overweight | 4 months ago |
|
5
Dyne Therapeutics
DYN
$1.88B
| $13.24 | $48 |
263%
upside
| Overweight | 6 months ago |
|
|
MESO
6
Mesoblast
MESO
$1.73B
| $13.52 | $24 |
78%
upside
| Overweight | 6 months ago |
|
7
Legend Biotech
LEGN
$6.46B
| $34.99 | $78 |
123%
upside
| Overweight | 8 months ago |
|
8
Xencor
XNCR
$597M
| $8.37 | $30 |
258%
upside
| Overweight | 9 months ago |
|
9
Arrowhead Research
ARWR
$3.87B
| $28 | $45 |
61%
upside
| Overweight | 9 months ago |
|
10
Moderna
MRNA
$9.45B
| $24.28 | $69 |
184%
upside
| Overweight | 9 months ago |
|
11
Capricor Therapeutics
CAPR
$272M
| $5.94 | $35 |
489%
upside
| Overweight | 10 months ago |
|
12
Opko Health
OPK
$1.1B
| $1.38 | $3 |
117%
upside
| Overweight | 11 months ago |
|
13
Monte Rosa Therapeutics
GLUE
$303M
| $4.91 | $16 |
226%
upside
| Overweight | 1 year ago |
|
14
Kymera Therapeutics
KYMR
$3.02B
| $42.20 | $56 |
33%
upside
| Overweight | 1 year ago |
|
|
PRTC
15
PureTech Health
PRTC
$383M
| $15.86 | $44 |
177%
upside
| Overweight | 3 years ago |
|
|
BCYC
16
Bicycle Therapeutics
BCYC
$483M
| $6.97 | $37 |
431%
upside
| Overweight | 3 years ago |
|
17
argenx
ARGX
$44.9B
| $733.66 | $354 |
52%
downside
| Overweight | 3 years ago |
|
18
Vertex Pharmaceuticals
VRTX
$102B
| $396.93 | $323 |
19%
downside
| Overweight | 4 years ago |
|
19
Exelixis
EXEL
$10.1B
| $37.38 | $36 |
4%
downside
| Overweight | 4 years ago |
|